An observational study in Delayed Diagnosis Pulmonary Hypertension, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hypertension, Pulmonary by Assiut University — 9 open to participants now, 9 under way, none of them phase 3. Hypertension, Pulmonary · Assiut University.
Among the 15 studies in Hypertension, Pulmonary by Assiut University, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2026, is one of 11 observational ones, and was the 13th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →9 of the 15 studies in Hypertension, Pulmonary by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18+
Assiut University
Ages up to 28 days
Assiut University · Sites in Egypt
Ages 40+
Assiut University · Sites in Egypt
Ages 18+
Assiut University
Ages 18–65
By country, each count listing its studies:
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1
First in 2015; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 110 across 380 observational studies indexed under Hypertension, Pulmonary.
Median enrollment 49 across the 4 interventional studies, 80 across the 11 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
4 of the studies in Hypertension, Pulmonary by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07184060Assiut UniversityEchocardiographic Assessment of Pulmonary Hypertension in Obstructive Sleep Apnea | 2027-04-30 |
| NCT07822750Assiut UniversityPredictors of Outcomes in Pulmonary Hypertension of the Newborn | 2027-09-10 |
| NCT07834918Assiut UniversityPulmonary Hypertension and RV Dysfunction in Myeloproliferative Neoplasms | 2027-09-20 |
| NCT07810881Assiut UniversityDiagnostic Delay in PHTN | 2027-11-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Hypertension, Pulmonary by Assiut University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Pulmonary hypertension (PH) is a progressive cardiopulmonary condition that may remain undiagnosed for a prolonged period because its initial symptoms are often nonspecific. This study aims to assess the relationship between diagnostic delay and disease severity at the time of initial presentation among adult patients with pulmonary hypertension at Assiut University Heart Hospital. The study will use an observational cross-sectional analytical design with retrospective review of available medical records and prospective data collection. Eligible patients will be consecutively recruited. Data will include demographic and clinical characteristics, duration of symptoms before diagnosis, previous medical consultations and diagnoses, WHO functional class, six-minute walk distance, echocardiographic findings, laboratory investigations, and available right heart catheterization data. The primary outcome is advanced disease at presentation, defined as WHO functional class III-IV. The study will also assess clinical, echocardiographic, functional, and hemodynamic markers of disease severity and potential factors associated with diagnostic delay.
Pulmonary hypertension (PH) is a complex cardiopulmonary syndrome associated with progressive pulmonary vascular disease and right ventricular overload. Its early clinical manifestations, including exertional dyspnea, fatigue, reduced exercise tolerance, chest discomfort, palpitations, presyncope, syncope, and peripheral edema, are often nonspecific and may overlap with common cardiac, respiratory, hematological, and other conditions. This may contribute to delayed recognition and referral for specialist assessment.
The present study aims to assess the relationship between the duration of diagnostic delay and disease severity at the time of initial presentation among adult patients with pulmonary hypertension attending the Pulmonary Hypertension Unit at Assiut University Heart Hospital. The study will also identify potential patient- and healthcare-related factors associated with delayed diagnosis.
This will be an observational cross-sectional analytical study with retrospective chart review and prospective data collection. Consecutive sampling will be used. All eligible adult patients with pulmonary hypertension fulfilling the predefined inclusion criteria will be recruited until the required sample size is reached. Patients identified from previously available medical records may be included when the required clinical and investigation data are available and the patient fulfills the eligibility criteria. Relevant prospective data will be collected during the study period.
Eligible participants will be adults aged 18 years or older with pulmonary hypertension diagnosed by right heart catheterization when available, or based on high echocardiographic probability or clinician diagnosis when right heart catheterization is not available. Participants should have baseline clinical assessment at or near the time of diagnosis or first presentation and should be able to provide an approximate date or month/year of the first PH-related symptom. Patients with unreliable information regarding symptom onset without alternative documentation, incomplete baseline data preventing assessment of disease severity, acute pulmonary embolism as the sole acute cause of transient pulmonary pressure elevation, or inability to complete the required assessment will be excluded.
Data will be collected using a structured case report form, standardized questionnaire, and review of available clinical records and investigations. Information will include demographic characteristics, residence, occupation, education, smoking status, comorbidities, presenting symptoms, date of first PH-related symptom, date of first medical consultation, initially consulted specialty, number of physicians visited, previous diagnoses, date of first echocardiography, date of suspected PH diagnosis, date of confirmed diagnosis, and patient-reported reasons for diagnostic delay.
Clinical assessment will include symptoms and signs of right-sided heart failure, WHO functional class, vital signs, oxygen saturation, relevant comorbidities, and medications. Functional capacity will be assessed using the six-minute walk distance when available. Available laboratory investigations, particularly hemoglobin and serum creatinine, will be recorded.
Available baseline echocardiographic data will be reviewed, including right atrial size, right ventricular basal diameter, RV systolic function, TAPSE, TR velocity, estimated pulmonary artery systolic pressure, IVC diameter and collapsibility, pericardial effusion, LV ejection fraction, LV diastolic function, left atrial size, valvular disease, and congenital shunts when present.
Right heart catheterization data will be recorded when available as part of routine clinical care, including right atrial pressure, right ventricular pressure, pulmonary artery pressures, pulmonary artery wedge pressure, pulmonary vascular resistance, cardiac output, cardiac index, pulmonary artery/mixed venous oxygen saturation, systemic blood pressure, and vasoreactivity testing results. Right heart catheterization will not be performed solely for research purposes.
The primary outcome will be advanced disease at initial presentation, defined as WHO functional class III-IV. Secondary outcomes will include six-minute walk distance below 300 meters, TAPSE below 17 mm, moderate or severe RV systolic dysfunction, moderate or severe right atrial or right ventricular dilatation, moderate or severe tricuspid regurgitation, pericardial effusion, clinical signs of right-heart failure, hospitalization before diagnosis, and high-risk right heart catheterization features such as elevated right atrial pressure, low cardiac index, and high pulmonary vascular resistance.
Exploratory outcomes will include the number of physicians visited before diagnosis, the first specialty consulted, initial misdiagnosis, and patient-reported causes of diagnostic delay.
Data will be analyzed using appropriate statistical methods. Categorical variables will be compared using the Chi-square or Fisher's exact test, while continuous variables will be analyzed using the independent-samples t-test or Mann-Whitney U test according to data distribution. Correlation analysis will assess the relationship between diagnostic delay in months and continuous severity markers. Multivariable logistic regression will be used to identify independent predictors of advanced disease presentation, with WHO functional class III-IV as the dependent variable. Odds ratios with 95% confidence intervals will be reported, and a two-sided p-value \<0.05 will be considered statistically significant.
Medical records will be used whenever possible to verify important dates and investigation results in order to reduce recall bias. No additional invasive procedure will be performed solely for research purposes, and all investigations will be recorded only when performed as part of routine clinical care.
Adult patients (aged 18 years or older) with pulmonary hypertension who present to the Pulmonary Hypertension Unit/Cardiology Department at Assiut University Heart Hospital during the study period. Participants will include patients with pulmonary hypertension confirmed by right heart catheterization when available, or patients with high echocardiographic probability or a clinician diagnosis of pulmonary hypertension when right heart catheterization is not available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Age 18 years or older
2. Patients with pre-capillary pulmonary hypertension, Group 1 PAH, Group 3 PH associated with lung disease/hypoxia, Group 4 chronic thromboembolic pulmonary hypertension (CTEPH) or other pulmonary artery obstructions, and Group 5 PH with unclear or multifactorial mechanisms.
3. Diagnosis of pulmonary hypertension based on RHC when available, or high echocardiographic probability/clinician diagnosis of PH when RHC is not available.
4. Availability of baseline clinical assessment at or near the time of diagnosis or first PH-unit presentation.
5. Ability to provide an approximate date or month/year of first PH-related symptom.
6. Willingness to participate and provide .
Exclusion Criteria:
1. Inability to provide reliable information about symptom onset and no alternative documentation in the medical record.
2. Incomplete baseline data preventing classification of disease severity. 3. Post-capillary pulmonary hypertension due to left heart disease (Group 2 PH).
4. Acute pulmonary embolism as the sole acute cause of transient pulmonary pressure elevation at presentation.
5. Severe acute illness, cognitive impairment, or communication barrier preventing questionnaire completion.
6. Refusal to participate. 7. Optional exclusion according to committee preference: patients with isolated post-capillary PH due to left heart disease may be excluded if the aim is to focus on PAH/pre-capillary PH.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with pulmonary hypertension who fulfill the predefined inclusion criteria and are consecutively recruited for assessment of diagnostic delay and disease severity at initial presentation. Data will be collected through structured questionnaires, clinical assessment, review of medical records, and available investigations.
Advanced disease at initial presentation
The primary outcome is the difference in the proportion of patients with WHO functional class III-IV between the early- and delayed-diagnosis groups at the initial presentation.
Time frame: at the time of diagnosis.
Advanced disease at initial presentation
The primary outcome is the difference in the proportion of patients with WHO functional class III-IV between the early- and delayed-diagnosis groups at the initial presentation
Time frame: At the initial presentation
No study locations are listed for this record.
Plan to share: No — There is no plan to share individual participant-level data (IPD). Data will be kept confidential and will be accessible only to the research team.
Start is estimated for Sep 2026; primary completion for Nov 2027, 14 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.